Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy Podcast Por arte de portada

Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy

Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy

Escúchala gratis

Ver detalles del espectáculo

Acerca de esta escucha

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics:

  • Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00)
  • Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50)
  • Published Clinical Data Involving Axi-cel (10:24)
  • Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34)
  • Published Clinical Data Involving Tis-cel (19:47)
  • Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43)
  • Published Clinical Data Involving Liso-cel (26:05)
  • Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48)
  • Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35)
  • Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59)

CME information and select publications
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones